Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JNJ

Blue-chip companies, characterized by large capitalization, global footprint, solid financial performance, robust balance sheet, and dominant market position, are favored by investors seeking stability and long-term growth potential. Thus, quality blue-chip stocks Microsoft (MSFT), Procter & Gamble (PG), and Johnson & Johnson (JNJ) could be attractive buys for steady returns.…

StockNews.com

How Is Johnson & Johnson's Stock Performance Compared to Other Pharmaceutical Stocks?

Johnson & Johnson has recently underperformed other pharmaceutical stocks. However, Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

Top 4 Pharma Stocks for Long-Term Value Investors in 2024

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Are Wall Street Analysts Bullish on Johnson & Johnson Stock?

As Johnson & Johnson trails the broader market, Wall Street analysts remain cautiously optimistic about the stock's prospects.

Barchart

Analyst updates Johnson & Johnson stock price target after earnings

This is what could happen next to Johnson & Johnson shares.

The Street

JNJ Earnings Forecast - Is Pharmaceutical Industry Set for Shake-up?

As pharma titan Johnson & Johnson (JNJ) gears up to unveil its first-quarter results on April 16, 2024, anticipation looms over the pharmaceutical industry. JNJ’s recent acquisitions signal the company’s strategic expansions, and given its history as one of the prominent pharma companies, is JNJ’s forecast as stunning? Let us…

StockNews.com

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson Poised For Growth Despite Recent Challenges

Johnson & Johnson (NYSE: JNJ) poised for growth despite challenges, with analysts estimating a 10% upside. Resilient in market fluctuations, key drivers in...

Top News

4 Pharma Titans Making Waves in Wall Street

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…

StockNews.com

3 Pharma Stocks With Prescription for Stability and Value in March

Amid rising healthcare demand globally, advancements in precision medicine, and the booming e-pharmacy market, the pharmaceutical industry is expected to witness significant long-term growth. Hence, fundamentally sound pharma stocks Dr. Reddy’s Laboratories (RDY), Ipsen (IPSEY), and Johnson & Johnson (JNJ), which boast low beta values and attractive valuation metrics, might…

StockNews.com

4 Top Dividend Kings to Earn Passive Income

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

Barchart

Pfizer (PFE) vs. Johnson & Johnson (JNJ) - Analyzing Pharma Stocks for Upside Potential

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

StockNews.com

3 Pharma Stock Buys With Accelerating Gains

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson & Johnson (JNJ) might be ideal additions to your portfolio for gains. Read on.

StockNews.com

J&J Flashes A Sell Signal Despite A MedTech Beat That Bodes Well For Its Rivals

Johnson & Johnson beat fourth-quarter expectations Tuesday, helped by strength from its medtech segment. But JNJ stock toppled.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Johnson & Johnson (JNJ): Analyzing Signals Before Quarterly Earnings

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company’s fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out….

StockNews.com

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

Barchart

2 Dividend Kings Yielding Around 3% to Grab Now

High yields aren't the only reason to buy shares of dividend-paying stocks. For investors seeking quality dividend stocks for passive income, here's a look at two companies with long track records of raising shareholder payouts.

StockNews.com

3 Pharma Stock Buys for Last-Minute Year-End Profits

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Catalyst Pharmaceuticals (CPRX) vs. Johnson & Johnson (JNJ): Predicting the Dominant Pharma Stock in 2024

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….

StockNews.com

Analyzing 3 Pharma Stocks for Year-End Gains?

The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read…

StockNews.com

3 Solid Pharma Stocks for a Healthy Year-End Portfolio

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

StockNews.com

3 Pharma Stocks Navigating Future Investments - Buy Now

The pharmaceutical industry is evolving with changing consumer behavior, rapid adoption of digital solutions, and global expansion. Hence, fundamentally strong pharma stocks Zoetis (ZTS), Wave Life Sciences (WVE), and Johnson & Johnson (JNJ) might be solid investments now. Read more….

Barchart

2 Dividend Kings Warren Buffett Just Dumped

The legendary value investor slashed two consistent dividend-paying stocks from Berkshire Hathaway's portfolio in the latest quarter, according to regulatory filings.

StockNews.com

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

StockNews.com

3 Pharma Stocks to Capitalize on With Potential Upside

The pharma industry’s prospects look bright, thanks to rising demand for innovative drugs. Thus, pharma stocks with potential upside, like GSK plc (GSK), Johnson & Johnson (JNJ), and Bristol-Myers Squibb Company (BMY), could be wise investments to capitalize on right now. Read on….

1 2 3 4 5

People

Warren Buffett

1,319 stories

Dipanjan BanchurSince

722 stories

Kritika SarmahHer

694 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Microsoft Corporation

241 stories

AbbVie

236 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.